|
市場調查報告書
醫藥業新技術取得合約
Dealmaking and Financing: Buying in Innovation
|
醫藥業新技術取得合約 是由出版商Decision Resources, Inc.在2008年03月所出版的。
這份英文市場調查報告書包含48 Pages 價格從美金2250起跳。
本報告書內容包括：醫藥業開發成本的上升、專利到期、與學名藥的競爭問題、公司內研發、育成者等推動藥物研發事業的各種實例研究、藥物研發、產品取得、授權等相關企業合約、醫藥業的新產品與新技術其初期階段的投入策略等等，內容綱要摘記如下：
摘要
摘要
產業受到更大壓力
- 規範監督擴大與認可延期
- 研發成本擴大與產能問題
- 專利到期與學名藥的競爭
- 生技藥物的混亂觀察
具體化：邁向技術革新與藥物研發的推進
- 新研發模式
- 邁向技術革新：公司內研發
- 推進藥物研發的育成者
價值構築的機會
技術革新：2000-2007年
- 產品合約
- 最近研發活動：2005-2007年
- 最終產品授權階段的主要企業：2005-2007年
大企業已認可產品的合約
- GlaxoSmithKline：對應多種病症的授權產品
- AstraZeneca：推動Biologics策略
- Novartis：採用獨創的合約結構
- Pfizer：致力於組織重組與公司外機會
- Merck & Co.：聚焦於取得小企業
- Johnson & Johnson：與小企業共享know-how
- Schering-Plough：大規模轉向
- Sanofi -Aventis：主要為胃藥物生產線
- Eli Lilly：最近收購與新授權活動
影響醫藥業合約環境的主要15大動向
圖表
Abstract
Introduction:
Pharmaceutical companies are on the hunt for new product and technology
opportunities to augment their product development pipelines. Pharmaceutical
giants and big biotech alike are exploring new avenues of cooperation to gain
early access to innovation as they move toward external R&D models and
establish corporate venturing infrastructures. Competition is fi erce. Right
now, innovation is the currency of the industry; it greases the wheels of
dealmaking, and its value is measured in the 4,030 products that were licensed
between 2005 and 2007 and the 15 drug licensing trends that this dealmaking is
spawning.
Get the Answers You Need to Shape Your Strategy:
- The near-term outlook for the pharmaceutical industry is not encouraging.
What is pharma' s new externalized R&D business model, and why is it
important?
- Patent expiries and disruption from biogenerics are two of the biggest
concerns looming in the industry right now. What are companies doing to
improve the outlook for their productivity and performance? What are the most
effi cient strategies for building value now? How do these strategies make
drug development more successful?
- Pharma is currently in an innovation defi cit. What vehicles are in
play for accessing innovation, and what trends are developing?
- Strategic opportunities such as licensing and partner deals among big
pharma, biotech, and specialty pharmaceutical companies are driving pipeline
development. What are the latest dealmaking strategies? What are some of
the big alliance deals already in motion?
Scope:
- Expert commentaries: analysis of corporate venturing and
value-added drug development by two industry experts.
- Mounting industry pressures: increasing regulatory oversight;
rising development costs and productivity problems; looming patent expiries;
generics competition; and disruption from biogenerics.
- Externalization trends in business practices: a new R&D model;
corporate venturing and innovation incubators to gain access to early-stage
innovation.
- Value-building opportunities: harnessing external innovation to
improve a product' s characteristics; chemical modifi cation as a
value-building opportunity.
- Acquiring innovation: a look at 4,030 products involved in product
deals from 2000-2007; fortifying pipelines via deal structures for product
acquisition, inlicensing, outlicensing, and joint ventures; late-stage product
inlicensing trends, 2005-2007.
- Big pharma' s inlicensed product deals: pharmaceutical companies tap
new resources by inlicensing late-stage products; inlicensed product
portfolios of nine major pharmaceutical companies; strategies used by
different companies.
- Recent dealmaking activities: an analysis of 15 trends infl uencing
the drug licensing landscape.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Industry Pressures Continue to Mount
- Increasing Regulatory Oversight and Delay
- Increasing Development Costs and Productivity Problems
- Patent Expiry and Generics Competition
- Expected Disruption from Biogenerics
- Externalization: Accessing Innovation and Fostering Drug Discovery
- New R&D Model
- Using Corporate Venturing to Access Innovation
- Innovation Incubators to Foster Drug Discovery
- Value-Building Opportunities
- Acquiring Innovation, 2000-2007
- Product Deals
- Recent Inlicensing Activity, 2005-2007
- Leading Companies in Late-Stage Product Inlicensing, 2005-2007
- Big Pharma' s Inlicensed Product Deals
- GlaxoSmithKline Inlicensed Products Across Several Disease Indications
- AstraZeneca Accelerates Its Biologics Strategy
- Novartis Employs Very Creative Deal Structures
- Pfi zer Restructures and Emphasizes External Opportunities
- Merck & Co. Looks to Small Company Acquisitions
- Johnson & Johnson Shares Know-How with Smaller Companies
- Schering-Plough in a Major Turnaround But Still Does Business
- Sanofi -Aventis, a Leading Pipeline for the Future
- Eli Lilly and Company' s Recent Acquisition and New Inlicensing Activity
- 15 Recent Trends Infl uencing Pharma' s Dealmaking Landscape
Spectrum Expert Commentaries:
- Corporate Venturing: A Cure for Pharma' s Innovation Ills?
- Capturing Additional Value in Drug Discovery and Development
Experts Featured:
Graeme R. Martin, Ph.D., president and chief executive offi cer, Takeda
Research Investment, Inc. Jeff Morhet, chairman and chief executive offi cer,
InNexus Biotechnology, Inc
Tables:
- 1. Patent Expiries in Major Markets of the 10 Top-Selling 2006 Blockbusters
- 2. Impending Patent Expiries for Select Biologics
- 3. Select GlaxoSmithKline Inlicensed Late-Stage Product Deals, 2007
- 4. Select AstraZeneca Inlicensed Late-Stage Product Deals, 2007
- 5. Select Novartis Inlicensed Late-Stage Product Deals, 2006-2007
- 6. Select Pfi zer Inlicensed Late-Stage Product Deals, 2005-2007
- 7. Select Merck & Co. Inlicensed Late-Stage Product Deals, 2006-2007
- 8. Select Johnson & Johnson Inlicensed Late-Stage Product Deals, 2005-2007
- 9. Select Schering-Plough Inlicensed Late-Stage Product Deals, 2006-2007
- 10. Select Sanofi -Aventis Inlicensed Late-Stage Product Deals, 2006-2007
- 11. Select Eli Lilly and Company Inlicensed Late-Stage Product Deals, 2007
Figures:
- 1. Acquiring Innovation
- 2. Trends in Original NDAs, BLAs, and NMEs Submitted to the FDA, 2002-2006
- 3. Number of Products Involved in Deals, 2000-2007
- 4. Product Dealmaking Activities Between Companies, 2000-2007
- 5. Phase of Development of 831 Inlicensed Products, 2005-2007
- 6. Categories of Inlicensed Products in Late-Stage Deals, 2005-2007
- 7. Companies That Lead in Late-Stage Product Inlicensing, 2005-2007
Expert A: Licenses and Options Executed by Start-Up, Small, and Large
Companies: Exclusive vs. Nonexclusive, 2006
|
